Caffeoylated Phenylpropanoid Glycosides from Brandisia hancei Inhibit Advanced Glycation End Product Formation and Aldose Reductase in Vitro and Vessel Dilation in Larval Zebrafish in Vivo

Abstract

In our continuing efforts to identify effective naturally sourced agents for diabetic complications, five caffeoylated phenylpropanoid glycosides, acteoside (1), isoacteoside (2), poliumoside (3), brandioside (4), and pheliposide (5) were isolated from the 80 % EtOH extract of Brandisia hancei stems and leaves. These isolates (1–5) were subjected to an in vitro bioassay evaluating their inhibitory activity on advanced glycation end product formation and rat lens aldose reductase activity. All tested compounds exhibited significant inhibition of advanced glycation end product formation with IC₅₀ values of 4.6–25.7 µM, compared with those of aminoguanidine (IC₅₀ = 1056 µM) and quercetin (IC₅₀ = 28.4 µM) as positive controls. In the rat lens aldose reductase assay, acteoside, isoacteoside, and poliumoside exhibited greater inhibitory effects on rat lens aldose reductase with IC₅₀ values of 0.83, 0.83, and 0.85 µM, respectively, than those of the positive controls, 3,3-tetramethyleneglutaric acid (IC₅₀ = 4.03 µM) and quercetin (IC₅₀ = 7.2 µM). In addition, the effect of acteoside on the dilation of hyaloid-retinal vessels induced by high glucose in larval zebrafish was investigated. Acteoside reduced the diameters of high glucose-induced hyaloid-retinal vessels by 69 % at 10 µM and 81 % at 20 µM, compared to the high glucose-treated control group. These results suggest that B. hancei and its active components might be beneficial in the treatment and prevention of diabetic vascular complications.

Key words

Brandisia hancei - Scrophulariaceae - phenylpropanoid glycoside - advanced glycation end-product - rat lens aldose reductase - zebrafish - diabetic vascular complications

^* These two authors contributed equally to this work.

• References

• 1 Wei M, Gaskill SP, Hanffner SM, Stern MP. Effect of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabet Care 1998; 21: 1167-1172
• 2 Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-942
• 3 Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790
• 4 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
• 5 Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-77
• 6 Morrison AD, Clements RS, Winegord AI. Effects of elevated glucose concentrations on the metabolism of the aortic wall. J Clin Invest 1972; 51: 3114-3123
• 7 Kinoshita JH. A thirty year journey in the polyol pathway. Exp Eye Res 1990; 50: 567-573
• 8 Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21-33
• 9 Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006; 11: 646-654
• 10 He ZD, Wang DZ, Yang CR. Phenylpropanoid glycosides from Brandisia hancei . Acta Bot Yunn 1990; 12: 439-446
• 11 He ZD, Yang CR. Brandioside, a phenylpropanoid glycoside from Brandisia hancei . Phytochemistry 1991; 30: 701-702
• 12 Kong LD, Wolfender JL, Cheng CH, Hostettmann K, Tan RX. Xanthine oxidase inhibitors from Brandisia hancei . Planta Med 1999; 65: 744-746
• 13 He ZD, Huang Y, Yao X, Lau CW, Law WI, Chen ZY. Purification of phenylethanoids from Brandisia hancei and the antiproliferative effects on aortic smooth muscle. Planta Med 2001; 67: 520-522
• 14 Lee YM, Kim YS, Kim JH, Kim JS. Screening of herbal medicines from China with inhibitory activity on advanced glycation end products (AGEs) formation (VI). Korean J Pharmacogn 2011; 42: 161-168
• 15 Li L, Rong T, Zhiqiang L, Shuying L, Raymond Y, Zhihong F. Isolation and purification of acteoside and isoacteoside from Plantago psyllium L. by high-speed counter-current chromatography. J Chromatogr A 2005; 1063: 161-169
• 16 Andary C, Privat G, Wylde R. Pheliposide and arenarioside, two new heterosidic esters isolated from caffeic acid of Orobanche arenaria . J Nat Prod 1985; 48: 778-783
• 17 Jang DS, Yoo NH, Kim NH, Lee YM, Kim CS, Kim J, Kim JH, Kim JS. 3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis. Biol Pharm Bull 2010; 33: 329-333
• 18 Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632
• 19 Kohda H, Tanaka S, Yamakoa Y, Yahara S, Nohara T, Tanimoto T, Tanaka A. Studies on lens-aldose-reductase inhibitor in medicinal plants. II. Active constituents of Monochasma savatierii Franch. Et Maxim. Chem Pharm Bull 1989; 37: 3153-3154
• 20 Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997; 150: 523-531
• 21 Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-2832
• 22 Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol 2003; 201: 328-333
• 23 Alvarez Y, Chen K, Reynolds AL, Waghorne N, OʼConnor JJ, Kennedy BN. Predominant cone photoreceptor dysfunction in a hyperglycaemic model of non-proliferative diabetic retinopathy. Dis Model Mech 2010; 3: 236-245
• 24 Matsuda H, Morokawa T, Toguchida I, Yoshikawa M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem Pharm Bull 2002; 50: 788-795
• 25 Matsuda H, Wang T, Managi H, Yoshikawa M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg Med Chem 2003; 11: 5317-5323
• 26 Lee J, Jang DS, Kim NH, Lee YM, Kim J, Kim JS. Galloyl glucoses from the seeds of Cornus officinalis with inhibitory activity against protein glycation, aldose reductase, and cataractogenesis ex vivo . Biol Pharm Bull 2011; 34: 443-446
• 27 Jang DS, Lee GY, Kim YS, Lee YM, Kim CS, Yoo JL, Kim JS. Anthraquinones from the seeds of Cassia tora with inhibitory activity on protein glycation and aldose reductase. Biol Pharm Bull 2007; 30: 2207-2210
• 28 de la Fuente JA, Manzanaro S. Aldose reductase inhibitors from natural sources. Nat Prod Rep 2003; 20: 243-251
• 29 Fujita T, Ohira K, Miyatake K, Nakana Y, Nakayama M. Inhibitory effects of perillosides A and C, and related monoterpene glycosides on aldose reductase and their structure activity relationships. Chem Pharm Bull 1995; 43: 920-926
• 30 Kurkin VA. Phenylpropanoids from medicinal plants: distribution, classification, structural analysis, and biological activity. Chem Nat Compd 2003; 39: 123-153
• 31 Pan J, Yuan C, Lin C, Jia Z, Zheng R. Pharmacological activities and mechanism of natural phenyl propanoid glycosides. Pharmazie 2003; 58: 767-775
• 32 Laporta O, Perez-Fons L, Balan K, Paper D, Cartagena V, Micol V. Bifunctional antioxidative oligosaccharides with antiinflammatory activity for joint health. Agro Food Ind Hi Tech 2004; 15: 30-33